Study of prevalence and effects of insulin resistance in patients with chronic hepatitis C genotype 4

A.F. Amer,1 M.M. Baddour,1 M.A. Elshazly,2 G. Fadally,1 N.F. Hanafi1 and S.L. Assar1

ABSTRACT There is strong epidemiological evidence linking hepatitis C virus (HCV) infection and diabetes. Our aim was to evaluate the prevalence of insulin resistance in Egyptian patients with chronic HCV genotype 4 infection, to assess factors associated with insulin resistance and to test the impact of insulin resistance on outcomes of treatment with pegylated interferon/ribavirin. Insulin resistance [homeostasis model assessment-insulin resistance (HOMA-IR) score > 3.0] was detected in 31 of 100 nondiabetic patients. The relationship between elevated HOMA-IR and baseline viral load and degree of fibrosis was statistically significant (r = 0.218 and r = 0.223). Follow-up of patients with complete early virological response until the end of treatment showed a statistically significant decrease in HOMA-IR score. Out of 29 liver tissue sections examined, 14 had a low level of expression of insulin receptor type 1 by immunohistochemical studies. This study confirms that insulin resistance affects treatment outcome, and thus HOMA-IR testing before initiation of therapy may be a cost–effective tool.

Étude de la prévalence et des effets de la résistance à l’insuline chez des patients atteints d’hépatite C de génotype-4

RÉSUMÉ Il existe des données factuelles épidémiologiques fortes reliant l’infection par le virus de l’hépatite C et le diabète. Nous avions pour objectif d’évaluer la prévalence de la résistance à l’insuline chez des patients égyptiens atteints d’une infection par le virus de l’hépatite C de génotype-4, d’étudier les facteurs associés à la résistance à l’insuline et de tester l’impact de la résistance à l’insuline sur les résultats du traitement par interféron pégylé/ribavirine. La résistance à l’insuline (score du modèle d’évaluation homéostatique pour l’insulino-résistance [HOMA-IR] > 3,0) a été observée chez 31 des 100 patients non diabétiques. Le lien entre un score HOMA-IR élevé et la charge virale initiale ainsi que le degré de fibrose était statistiquement significatif (r = 0.218 et r = 0.223). Le suivi des patients ayant présenté une réponse virologique précoce et complète jusqu’à la fin du traitement a révélé une diminution statistiquement significative du score HOMA-IR. Sur les 29 coupes de tissu hépatique examinées, 14 présentaient un faible niveau d’expression du récepteur insulìnique de type 1 selon les études immunohistochimiques. La présente étude confirme que la résistance insulaire influe sur les résultats du traitement. Par conséquent, le score HOMA-IR avant l’instauration d’un traitement peut être un outil d’un bon rapport coût-efficacité.

1Department of Medical Microbiology and Immunology, Faculty of Medicine; 2Department of Tropical Medicine, Faculty of Medicine; 3Department of Pathology, Medical Research Institute, University of Alexandria, Alexandria, Egypt (Correspondence to S.L. Assar: sara_asar1@yahoo.com).

Received: 02/12/14; accepted: 29/07/15
Introduction

For many years, Egypt has been widely regarded as having an epidemic of hepatitis C virus (HCV) infection, with the highest recorded prevalence in the world. HCV is currently the most significant health problem in Egypt. The latest published Egyptian Demographic Health Survey in 2009 of a national probability sample of the resident population estimated an overall anti-HCV antibody prevalence of 14.7%. The proportion of Egyptians estimated to be chronically infected was 9.8% (1).

The current standard treatment for chronic HCV infection (CHC) is pegylated interferon-alpha (peg IFN-α) combined with ribavirin. Despite significant improvement in treatment efficacy during the past decade, only 50% of patients can be cured of HCV, depending on its genotype (2). Besides being unsatisfactory, treatment of HCV is costly, beyond the reach of most patients in Egypt, requires 48 or more weeks to complete and has serious side effects. New modalities of therapy using directly-acting antiviral drugs, are available in some national treatment units but are not yet fully implemented in all of them.

The spectrum of severity of liver disease associated with HCV varies widely and depends on both viral and host factors. Age, male sex, alcohol consumption, immune status and co-infections are defined as risk factors for a progressive course of CHC (3). One of the co-factors is type 2 diabetes (4). There is strong epidemiological evidence linking HCV and diabetes. Patients with HC are more likely to develop type 2 diabetes (5) and diabetic patients are more likely to be infected with HCV (6). Type 2 diabetes has been recognized to worsen the course of hepatitis C. Both are now recognized as being a deadly combination (7). In view of this association, instead of looking only at the occurrence of overt type 2 diabetes, we should also consider prediabetic conditions such as insulin resistance in patients with HCV infection. Insulin resistance is defined as a condition in which higher than normal insulin levels are needed to achieve normal glucose metabolism or alternatively normal insulin levels fail to achieve normal glucose metabolism (8).

During recent years, basic research, clinical trials and epidemiological studies have provided evidence that HCV can independently contribute to insulin resistance (9–11). Adding to this growing body of evidence, it is now suggested that HCV interferes with the insulin signalling pathway using genotype-specific mechanisms (12). Insulin carries out its biological effects through phosphorylation of insulin substrate receptors 1 (IRS-1) and 2 (IRS-2) (13). Thus research has focused on IRS-1 and -2 as the loci for insulin resistance. An association between HCV and insulin resistance would have significant clinical consequences. Mounting evidence indicates that HCV-associated insulin resistance may cause accelerated fibrogenesis, reduced response to interferon-based therapy and hepatocellular carcinoma (14). These life-threatening complications are different from the well-known complications of lifestyle-associated insulin resistance, namely cardiovascular diseases, renal failure and infections (15).

Increased levels of insulin resistance are associated with reduced rates of initial virological response as well as sustained virological response in CHC patients treated with a combination of peg IFN-α and ribavirin (16,17). This negative association has been reported not only in patients infected with genotype 1 (17), but also in those with the so-called “easy to treat” genotypes 2 and 3 (18). Conversely, development of insulin resistance or exacerbation of previously stable glycemic control have been reported as drug side-effects in CHC patients who are receiving interferon treatment (19). To our knowledge, studies concerning genotype 4, the most prevalent genotype in Egypt (20), are limited. Information regarding glucose abnormalities in CHC patients with genotype 4 is valuable for determining if strategies to modify insulin resistance before or during combination therapy are a feasible approach for enhancing the likelihood of treatment response.

Our aim was to evaluate the prevalence of insulin resistance in Egyptian patients chronically infected with HCV genotype 4, to assess factors associated with insulin resistance in those patients (viral, metabolic and histopathological, including steatosis, fibrosis and necro-inflammatory changes) and to test the impact of insulin resistance on treatment outcomes in patients receiving peg IFN-α and ribavirin treatment.

Methods

This study was conducted from January 2013 to January 2014. The study received ethical approval from the local research committee of Alexandria Main University Hospital. All patients and controls were asked to give their informed consent before being included in the study.

Study sample

A total of 100 adult patients with CHC genotype 4 infection were enrolled randomly from the centre for treatment of hepatitis viruses in Sharq El Madina Hospital of Alexandria, Egypt. The hospital is one of 23 centres established by the Egyptian Ministry of Health for treating CHC patients as a part of the national viral hepatitis treatment programme.

All patients were eligible for treatment and non-diabetic (diabetes was diagnosed using the 1997 American Diabetes Association criterion: fasting glucose > 126 mg/dL). The following patients were excluded from the study by appropriate virological, serological, biochemical and ultrasound data and
by clinical history: those with clinical evidence of hepatic decompensation or liver cirrhosis, concomitant hepatitis B infection (defined as HBsAg-positive), patients with CHC of a genotype other than 4, autoimmune hepatitis, hemochromatosis, primary biliary cirrhosis, Wilson disease, drug-induced liver disease and laboratory values of serum creatinine > 1.5 mg/dL, absolute neutrophil count < 1000/mL, platelet count < 50 000/mL or haemoglobin < 11 g/dL. Randomization was done on the basis of the exclusion and inclusion criteria that were applied to all patients and was performed on the days of data collection for all patients attending the treatment centre on that day.

A control group comprising 60 healthy HCV-antibody negative individuals from the general population was included in the study for comparing their homeostasis model assessment—insulin resistance (HOMA-IR) index with that of the CHC patients. Our controls were individuals entering the laboratory for enzyme-linked immunosorbent assay (ELISA)-HCV antibody test and, when a negative result was obtained, an additional HOMA-IR test was performed to determine their insulin resistance and to compare it with insulin resistance among CHC patients.

The sample size calculation for the study was done by an experienced statistician. The sampling protocol was as follows. A total of 100 patients attending the national treatment centre for HCV provided by the national treatment programme were to be included for a cross-sectional study of the prevalence of insulin resistance among CHC patients. From these 100 patients, 60 patients were to be followed for studying the different treatment outcomes and to follow their insulin resistance state.

After 12 weeks from starting treatment, 10 patients were non-responders and their treatment was stopped according to the Ministry of Health protocol. We therefore followed another 11 patients making a total of 71 patients followed for treatment response and insulin resistance.

### Data collection

#### Clinical and demographic data

Clinical and demographic data were collected from the patients’ files, including: age, sex, height, weight, waist circumference and blood pressure. Venous blood samples were collected from both cases and controls after they had fasted overnight for 12 hours, to test their lipid profile and to determine serum levels of glucose and insulin.

Body mass index (BMI) was calculated. The metabolic syndrome was diagnosed according to the revised World Health Organization (WHO) definition as the presence of 3 or more of the following criteria: central obesity (waist circumference > 102 cm in males or > 88 cm in females), hypertension (blood pressure > 135/85 mmHg), fasting plasma glucose > 110 mg/dL, triglycerides > 150 mg/dL, high density lipoprotein (HDL) cholesterol < 40 mg/dL (males) or < 50 mg/dL (females) (21).

### HOMA method

Insulin resistance was assessed using the HOMA method using an immunoassay analyser (COBAS E insulin kit immunoassay analyser, Roche Diagnostics) and the following equation: HOMA-IR = fasting insulin (µU/mL) \times fasting glucose (mmol/L)/22.5 (22). A HOMA-IR score > 3.0 was considered the criterion for insulin resistance (23).

### Virological assessments

Assessment of the HCV viral load of the 100 patients included in our study was done by quantitative measurement of RNA using real-time PCR (COBAS AmpliPrep/COBAS TaqManT, Roche Molecular Systems). Level of viraemia was classified as high, intermediate and low according to viral load being > 10^6, 10^5–10^6 or < 10^5 IU/mL respectively (24). Determination of the genotype of the virus was done using a real-time PCR kit (AmpliSens HCV-FRT, InterLabService Ltd). The definition of the on-treatment response was as follows: complete early virological response was defined as HCV-RNA below the limit of detection at week 12. Partial early virological response was defined as positive HCV-RNA at week 12 but with a ≥ 2 log10 drop in viral load as compared with baseline. End-of-treatment response was defined as serum HCV-RNA below the limit of detection at the end of treatment. We considered non-responders to be: patients with no or minimal change in their HCV-RNA titres (< 2 log10 drop at week 12 as compared with baseline); those with viral load drop > 2 log10 at week 12 as compared with baseline and who still had positive HCV-RNA at week 24; those who became HCV-RNA positive after negativization before the end of treatment (breakthrough response); and those who became HCV-RNA positive after negativization at the end of treatment (25).

#### Treatment outcomes

From the 100 patients enrolled in the study, 71 treatment-naïve CHC patients (i.e. those who had not had received any form of treatment for HCV by any private- or government-sector physician) were followed for treatment outcomes associated with various degrees of insulin resistance. All patients were started on treatment with a combination of peg INF-α and ribavirin for an intended duration of 48 weeks, as in the protocol of the national HCV programme.

Serum HCV-RNA levels were assessed in all patients at baseline and then at weeks 12, 24 and 48. After 12 weeks, the early virological response was assessed by measuring the viral load and the HOMA-IR score was determined. Patients who did not demonstrate a decrease in viral load of 2 log or more were considered early non-responders (n = 10) (26). Therapy was discontinued for these patients according to the protocol.
approved by the Ministry of Health. Patients showing a ≥ 2 log reduction in viral load continued the antiviral treatment regimen until 48 weeks (n = 61). Viral load and insulin resistance were reassessed again after 48 weeks of therapy.

Liver histopathology and immunohistochemistry

All patients underwent an ultrasound-guided percutaneous liver biopsy prior to the start of treatment and patients with hemochromatosis or primary biliary cirrhosis were excluded. The degree of necroinflammatory activity and of fibrosis were scored based on the Metavir system (27). Hepatic steatosis was scored as the percentage of hepatocytes containing macrovesicular fat droplets and was graded from 0 to 3 (28). Paraffin-embedded liver sections from selected patients were deparaffinized and subjected to immunohistochemical staining using an anti-human-IRS-1 (Ultravision detection system antipolyvalent, HRP/ DAB kit, Thermo Fischer Scientific) to examine the protein expression levels of IRS-1 (29).

Statistical analysis

The data were analysed using SPSS software package, version 20.0. Qualitative data were described using numbers and percentages. Quantitative data were described using the range (minimum and maximum), mean, standard deviation (SD) and median. Comparison between cases and controls was performed using the chi-squared test. The distributions of quantitative variables were tested for normality using Kolmogorov–Smirnov, Shapiro–Wilk and D’Agostino tests. If they revealed normal data distributions, parametric tests were applied. If the data were abnormally distributed, non-parametric tests were used. For abnormally distributed data, comparison between cases and controls was done using the Mann–Whitney test, while the Kruskal–Wallis test was used to compare between HOMA-IR categories. Correlations between HOMA-IR with different parameters were assessed using Spearman coefficient. Significance test results were quoted as 2-tailed probabilities. Significance of the obtained results was judged at the 5% level.

Results

Among the 100 CHC patients included in the study, 40 were males and 60 were females, with a mean age of 42.8 (SD 10.2) years. The mean BMI was 27.1 (SD 3.4) kg/m². A total of 15 patients fulfilled the criteria for the metabolic syndrome. According to the Metavir score, necroinflammation was moderate to severe in 45.0% of patients and fibrosis was significant in 49.0% of cases. Steatosis was moderate in 20.7% of cases and severe in 10.3% of cases.

Distribution of studied cases according to baseline viral load

The distribution of the 100 patients included in this study with respect to their baseline viral load was as follows: 22.0% had low level viraemia, 43.0% had intermediate level viraemia and 35.0% had high level viraemia. The median viral load was 487.3 ×10⁵ IU/mL with mean value of 2400.9 (SD 6854.8) ×10⁵ IU/mL.

Results of HOMA-IR

Insulin resistance was detected in 31 of the 100 non-diabetic CHC patients infected with genotype 4 (HOMA-IR > 3.0). When HOMA-IR scores were categorized into 3 groups (< 2, 2–4 and > 4), a highly significant difference was seen between patients and controls; for example, 49.0% of patients versus 73.3% of controls had HOMA-IR < 2 (P = 0.001) (Figure 1). The mean HOMA-IR scores of cases and controls were significantly different: 2.55 (SD 2.36) versus 1.61 (SD 1.29) (P < 0.001) (Table 1).

Relationship between HOMA-IR and clinical and biological variables

Data on the relationship between HOMA-IR and clinical and biological variables are shown in Table 2. HOMA-IR tended to correlate positively with age, baseline viral load, BMI, serum triglycerides, fibrosis and steatosis and negatively with total cholesterol, low- and high-density lipoprotein cholesterol and total lipids. Statistically significant correlations were found between elevated HOMA-IR and both baseline viral load (Spearman r = 0.218, P = 0.029) and degree of fibrosis (r = 0.223, P = 0.026).

When the data were analysed by multivariate linear regression, the results showed that viral load remained the only independent factor associated with elevated HOMA-IR levels (P = 0.001).

Relationship between insulin resistance and treatment response

Patients with a lower baseline HOMA score had more favourable outcomes regarding response to therapy. Patients who reached complete early virological response had statistically significant lower HOMA-IR scores than non-responders (Table 3). All patients with complete and partial early virological response achieved end-of-treatment response with no breakthrough response.

The values of HOMA-IR test at the start of therapy, after 12 weeks and after 48 weeks of therapy in CHC patients who attained complete early virological response showed a considerable decline in HOMA-IR level (P < 0.001), suggesting that insulin resistance improved with successful treatment (Table 4).

Relation between immunohistochemistry and HOMA-IR before therapy

The expression of IRS-1 was estimated by immunohistochemical staining of 29 liver tissue sections of CHC cases included in the study. The results were
as follows: 9 cases were grade 0 (10% positive cells), 6 cases were 1+ (10–50% positive cells with weak staining), 10 cases were 2+ (10–50% positive cells with strong staining or 50% positive cells with weak staining) and 4 were cases 3+ (50% positive cells with strong staining) (Figure 2) (30). No statistically significant difference was found between any grades of immunohistochemistry and HOMA-IR score before therapy (P = 0.942).

**Discussion**

This study was conducted to determine the prevalence of insulin resistance in non-diabetic patients with CHC genotype 4 and its effect on therapy and to reveal whether application of a simple and relatively inexpensive test for assessment of insulin resistance (HOMA score) before starting antiviral therapy will lead to better selection of patients who are candidates for successful treatment. The mean HOMA-IR score of the 100 patients undergoing treatment with dual therapy (peg-INF-α plus ribavirin) was 2.55 (SD 2.36). Insulin resistance, defined as HOMA-IR score > 3.0, was detected in 31 patients. In a study by Khattab et al., also conducted on CHC patients with genotype 4, the mean pretreatment HOMA-IR scores (using the cut-off > 2) was 2.82 (SD 1.19) (25). Similarly, Ezzat et al. found that among CHC genotype 4 patients 31 (40.7%) had insulin resistance, defined as HOMA-IR score > 2, and the mean HOMA-IR was 2.6 (31). Moucari et al. also studied CHC genotype 4 patients and found the HOMA-IR (using the cut-off > 3) was 3.7 (SD 4.0) (23). In Asselah et al.’s study of CHC genotype 4 patients the proportion with HOMA-IR > 3 was 32.4% (32).

In the correlational analysis, baseline viral load was a statistically significant factor affecting pre-treatment HOMA-IR (P = 0.029) and was the major independent factor associated with high HOMA-IR by linear regression analysis (P = 0.001). Similarly, Asselah et al. found that insulin resistance was significantly associated with basal viral load in univariate analysis (P = 0.008) as well as multiple logistic regression analysis (P = 0.02) (32). Moucari et al. also showed that insulin resistance had a statistically significant correlation with

**Table 1 Comparison of homeostatic model assessment–insulin resistance (HOMA-IR) scores between patients with chronic hepatitis C genotype 4 and control subjects**

<table>
<thead>
<tr>
<th>Group</th>
<th>HOMA-IR score</th>
<th>Mann–Whitney test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls (n = 60)</td>
<td>Mean (SD) 1.61 (1.29)</td>
<td>Median 1.41</td>
</tr>
<tr>
<td>Cases (n = 100)</td>
<td>Mean (SD) 2.55 (2.36)</td>
<td>Median 2.05</td>
</tr>
</tbody>
</table>

SD = standard deviation.

**Figure 1** Comparison of homeostatic model assessment–insulin resistance (HOMA-IR) scores in patients with chronic hepatitis C genotype 4 and control subjects at the 3 different cut-off levels (< 2, 2–4, > 4) (χ² = 9.168; P = 0.009)
serum HCV-RNA in univariate analysis ($P < 0.001$) and also in multiple logistic regression analysis ($P = 0.002$) (23). Our finding supports the hypothesis that HCV has a direct effect on insulin resistance progression in CHC patients. In contrast, another study by Ezzat et al. showed that insulin resistance had no impact on early virological response with combined therapy, on viral load or on necroinflammation (31). The contradiction between the findings of the current study and those of Ezzat et al. may be because they assessed HOMA-IR before therapy and at 12 weeks after therapy only and did not measure HOMA-IR at the end of treatment.

Concerning the relationship between pre-treatment values of HOMA-IR and response to therapy in patients with genotype 4 CHC infection, we concluded that having a lower baseline HOMA score led to a favourable therapeutic outcome. There was a statistically significant difference comparing the HOMA-IR of patients achieving complete early virological response, partial early virological response and non-response ($P = 0.006$). Likewise, Khattab et al. found a highly and significant relationship between insulin resistance and treatment response ($P < 0.001$) (25). Similarly, Moucari et al. concluded from their study that HOMA-IR score < 2 was associated with early virological response ($P < 0.001$) and also remained an independent predictor of sustained virological response by multiple logistic regression analysis ($P = 0.03$) (23).

This research also studied the effect of successful treatment on the insulin resistance state in the selected CHC patients. Follow-up of the complete early virological responders until the end of treatment showed that they had a statistically significant decrease

### Table 2

<table>
<thead>
<tr>
<th>Variable</th>
<th>Correlation with HOMA-IR score</th>
<th>$r_s$</th>
<th>$P$-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.101</td>
<td>0.315</td>
<td></td>
</tr>
<tr>
<td>Viral load</td>
<td>0.218</td>
<td>0.029</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>0.151</td>
<td>0.133</td>
<td></td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>-0.098</td>
<td>0.338</td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>0.118</td>
<td>0.246</td>
<td></td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>-0.081</td>
<td>0.430</td>
<td></td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>-0.120</td>
<td>0.238</td>
<td></td>
</tr>
<tr>
<td>Total lipids</td>
<td>-0.037</td>
<td>0.716</td>
<td></td>
</tr>
<tr>
<td>Fibrosis grade</td>
<td>0.223</td>
<td>0.026</td>
<td></td>
</tr>
<tr>
<td>Steatosis grade</td>
<td>0.336</td>
<td>0.075</td>
<td></td>
</tr>
</tbody>
</table>

$r_s$ = Spearman correlation coefficient.  
BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein.

### Table 3

<table>
<thead>
<tr>
<th>Response to therapy</th>
<th>Mann-Whitney test</th>
<th>HOMA-IR scores</th>
<th>SD</th>
<th>Median</th>
<th>Min.-Max.</th>
<th>$P^1$</th>
<th>$P^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early non-responders (n = 10)</td>
<td>-</td>
<td>2.95 (1.14)</td>
<td>3.07</td>
<td>1.10–4.67</td>
<td>-</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>Partial early virological response (n = 7)</td>
<td>0.435$^a$</td>
<td>3.98 (2.13)</td>
<td>3.66</td>
<td>1.90–8.24</td>
<td></td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Complete early virological response (n = 54)</td>
<td>0.037$^b$</td>
<td>2.32 (2.35)</td>
<td>1.64</td>
<td>0.37–11.66</td>
<td></td>
<td>0.007$^b$</td>
<td></td>
</tr>
</tbody>
</table>

Kruskal-Wallis test $\chi^2 = 10.303; P = 0.006$

$^a$ Versus early non-responders; $^b$ Versus partial early virological response; *Comparing groups. SD = standard deviation.

### Table 4

<table>
<thead>
<tr>
<th>Follow-up interval</th>
<th>Wilcoxon signed ranks test</th>
<th>HOMA-IR scores</th>
<th>SD</th>
<th>Median</th>
<th>Min.-Max.</th>
<th>$P^1$</th>
<th>$P^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-treatment (n = 54)</td>
<td>-</td>
<td>2.32 (2.35)</td>
<td>1.64</td>
<td>0.37–11.7</td>
<td>-</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>After 12 weeks therapy (n = 54)</td>
<td>0.081$^a$</td>
<td>2.20 (2.63)</td>
<td>1.39</td>
<td>0.20–15.1</td>
<td></td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>After 48 weeks therapy (n = 52)</td>
<td>-</td>
<td>1.66 (1.61)</td>
<td>1.20</td>
<td>0.13–10.5</td>
<td>&lt; 0.001$^b$</td>
<td></td>
<td>&lt; 0.001$^b$</td>
</tr>
</tbody>
</table>

Friedman test $\chi^2 = 27.038; P < 0.001$

$^a$ Versus pre-treatment; $^b$ Versus 12 weeks follow-up; *Comparing groups. SD = standard deviation.
in HOMA-IR ($P < 0.001$). Similarly, Brandman et al. showed that patients had a substantial decrease in insulin resistance level 6 months after receiving antiviral therapy in comparison with those not receiving treatment (33).

In this study, 29 liver tissue sections from selected cases were tested by immunohistochemistry for expression of IRS-1 to assess viral role in induction of insulin resistance state. Fourteen cases showed a high level of IRS-1 expression (grades 2+ and 3+) and 15 cases had a low level of expression (grades 0 and 1+) and there was no significant difference. Kawaguchi et al. demonstrated a 2- and 3-fold increase in the intensities of IRS-1 and IRS-2 staining respectively after antiviral therapy. They identified mechanisms for HCV-associated insulin resistance, postulating that HCV core downregulates hepatic expression of IRS-1/2, and thus decreases the core downregulates hepatic expression of IRS-1/2, and thus decreases the downstream signalling effect of insulin signaling. From the management point of view, we can ask: Should patients with CHC be monitored regularly for insulin resistance? HOMA-IR is a practical and well-accepted method of measuring insulin resistance and is a non-invasive, inexpensive test that can be implemented easily in routine clinical practice. Our study provides further evidence that insulin resistance affects treatment outcome and that HOMA-IR testing before initiation of therapy may be a cost–effective tool to be considered before treating patients. Moreover, this study supports the use of strategies to modify insulin resistance before or during combination therapy as a feasible approach for enhancing the likelihood of treatment response, especially for HCV genotype 4 patients. This study also points to future research on the effect of glucose abnormalities on newly approved drug therapies with directly acting antivirals, as they may be an attractive alternative for treating insulin-resistant CHC patients.

Finding: None declared.

Competing interests: None declared.

References


